BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 25128688)

  • 1. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.
    Parker S; Crump R; Foster S; Hartzler H; Hembrador E; Lanier ER; Painter G; Schriewer J; Trost LC; Buller RM
    Antiviral Res; 2014 Nov; 111():42-52. PubMed ID: 25128688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
    Crump R; Korom M; Buller RM; Parker S
    Antiviral Res; 2017 Mar; 139():112-116. PubMed ID: 28039021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox.
    Wei H; Huang D; Fortman J; Wang R; Shao L; Chen ZW
    J Virol; 2009 Jan; 83(2):1115-25. PubMed ID: 19004937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
    Parker S; Chen NG; Foster S; Hartzler H; Hembrador E; Hruby D; Jordan R; Lanier R; Painter G; Painter W; Sagartz JE; Schriewer J; Mark Buller R
    Antiviral Res; 2012 Apr; 94(1):44-53. PubMed ID: 22381921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.
    Israely T; Paran N; Lustig S; Erez N; Politi B; Shafferman A; Melamed S
    Virol J; 2012 Jun; 9():119. PubMed ID: 22709563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.
    Parker S; Siddiqui AM; Oberle C; Hembrador E; Lanier R; Painter G; Robertson A; Buller RM
    Virology; 2009 Mar; 385(1):11-21. PubMed ID: 19100593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
    Parker S; D'Angelo J; Buller RM; Smee DF; Lantto J; Nielsen H; Jensen A; Prichard M; George SL
    Antiviral Res; 2021 Nov; 195():105179. PubMed ID: 34530009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.
    Zaitseva M; McCullough KT; Cruz S; Thomas A; Diaz CG; Keilholz L; Grossi IM; Trost LC; Golding H
    J Virol; 2015 Mar; 89(6):3295-307. PubMed ID: 25589648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
    Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
    Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
    Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
    J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.
    Parker S; Touchette E; Oberle C; Almond M; Robertson A; Trost LC; Lampert B; Painter G; Buller RM
    Antiviral Res; 2008 Jan; 77(1):39-49. PubMed ID: 17904231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.
    Israely T; Melamed S; Achdout H; Erez N; Politi B; Waner T; Lustig S; Paran N
    PLoS One; 2014; 9(10):e110545. PubMed ID: 25350003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.
    Parker S; Schriewer J; Oberle C; Robertson A; Lanier R; Painter G; Buller RM
    Antivir Ther; 2008; 13(7):863-73. PubMed ID: 19043920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
    Rice AD; Adams MM; Lampert B; Foster S; Robertson A; Painter G; Moyer RW
    Viruses; 2011 Feb; 3(2):63-82. PubMed ID: 21369346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4.
    Robbins SJ; Jackson RJ; Fenner F; Beaton S; Medveczky J; Ramshaw IA; Ramsay AJ
    Antiviral Res; 2005 Apr; 66(1):1-7. PubMed ID: 15781125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits.
    Grossi IM; Foster SA; Gainey MR; Krile RT; Dunn JA; Brundage T; Khouri JM
    Antiviral Res; 2017 Jul; 143():278-286. PubMed ID: 28392420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model.
    Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA
    mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
    Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
    Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smallpox vaccination and adverse reactions. Guidance for clinicians.
    Cono J; Casey CG; Bell DM;
    MMWR Recomm Rep; 2003 Feb; 52(RR-4):1-28. PubMed ID: 12617510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.
    Xiao Y; Aldaz-Carroll L; Ortiz AM; Whitbeck JC; Alexander E; Lou H; Davis HL; Braciale TJ; Eisenberg RJ; Cohen GH; Isaacs SN
    Vaccine; 2007 Jan; 25(7):1214-24. PubMed ID: 17098336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.